Search Results

Syntactx Appoints Dr. David Deaton as Chief Medical Officer

February 1, 2017—Syntactx recently announced that David Deaton, MD, has joined the company as Chief Medical Officer.

PIVOTAL Study of EVAR Presented at TCT

September 24, 2009—When compared to surveillance, there was no apparent benefit to endovascular repair (EVAR) of small abdominal aortic aneurysms (AAAs) measuring between 4 and 5 cm, according to results from the PIVOTAL (Positive Impact of Endovascular Options for Treating Aneurysms Early) trial.

BD Announces Findings Supporting the Safety of Lutonix Paclitaxel-Coated Balloon

September 28, 2019—BD (Becton, Dickinson and Company) announced that findings from a company-initiated, independent analysis of its Lutonix 035 drug-coated balloon (DCB) femoropopliteal clinical program were published online by Kenneth Ouriel, MD, et al in Journal of the American College of Cardiology: Cardiovascular Interventions and simultaneously presented in a late-breaking trial session at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium held September 25–29 in San Francisco, California.

PIVOTAL Compares EVAR and Surveillance of Small AAAs

April 27, 2010—The Society for Vascular Surgery announced publication of the PIVOTAL (Positive Impact of Endovascular Options for Treating Aneurysms Early) study.

PIVOTAL Compares EVAR and Surveillance of Small AAAs

April 27, 2010—The Society for Vascular Surgery announced publication of the PIVOTAL (Positive Impact of Endovascular Options for Treating Aneurysms Early) study.

Cost and Quality-of-Life Data Compared for Early EVAR and Surveillance of Small AAAs

August 6, 2013—The Society for Vascular Surgery (SVS) announced publication of a study that compared the resource use, medical cost, and quality of life (QOL) outcomes for treatment strategies involving early endovascular repair (EVAR) versus surveillance with serial imaging studies for treatment of small (4–5 cm in diameter) abdominal aortic aneurysms (AAAs).

47th Annual VEITHsymposium Canceled; 48th Annual Meeting Now Planned for November 2021

September 24, 2020—The VEITHsymposium organizers announced they have canceled the 47th annual VEITHsymposium that was rescheduled to take place on February 23-27, 2021 in New York, New York.

Dorothy Abel Joins Syntactx as Vice President, Regulatory Strategy

February 6, 2020—Syntactx announced that Ms.

M2S and NAMSA Collaboration Will Nest Premarket Vascular Device Trials in Registries

June 22, 2021—M2S, a division of Medstreaming, and NAMSA announced a strategic collaboration combining M2S’s medical registry services and NAMSA’s expertise as a Contract Research Organization (CRO) to provide clinical trial services for vascular device manufacturers.

NAMSA Acquires Syntactx CRO Development Solutions

January 5, 2021—NAMSA, a medical device–focused contract research organization (CRO) providing full continuum development solutions, announced the acquisition of the CRO, Syntactx.